ARHGAP11A-SCG5 readthrough protein (ARHGAP11A-SCG5)

The ARHGAP11A-SCG5 readthrough gene is produced by a naturally occurring transcriptional readthrough event between the adjacent ARHGAP11A and SCG5 genes on chromosome 15q13.3, encoding a chimeric (fusion) protein composed of regions derived from both parent genes[5]. There is currently no evidence that this fusion protein possesses unique biological activity, therapeutic relevance, or established role as a receptor, enzyme, or classical drug target. The function, clinical significance, and therapeutic targeting potential of this fusion protein remain uncharacterized in the scientific literature. The molecule should not be considered a conventional therapeutic target or receptor, but rather a readthrough transcript with unclear function. There are no known drugs or clinical biomarkers directly linked to this fusion transcript. ARHGAP11A-SCG5 is a fusion protein generated by readthrough transcription between the ARHGAP11A and SCG5 genes; it is not a validated target, receptor, or actionable molecule and has no known function, biomarkers, drug interactions, or mechanisms of action as of the current literature and gene/protein annotation sources[2][5].

Other names

ARHGAP11A-SCG5 proteinARHGAP11A-SCG5 readthrough